Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India.

Autor: Jadhav UM; Cardiology, Cardiac CT and Cardiac MRI Department, MGM New Bombay Hospital, Navi Mumbai, India. umjadhav@gmail.com., Ray S; Sri Aurobindo Seva Kendra, AMRI Hospital Dhakuria, Kolkata, India., Unni TG; Jubilee Mission Medical College, Thrissur, India., Sawhney JPS; Sir Gangaram Hospital, Delhi, India., Mehta A; Sir Gangaram Hospital, Delhi, India., Guha S; Medical College, Kolkata, India., Karnik RD; Fortis Hospital, Mumbai, India., Desai BN; Desai Heart Care Clinic, Mumbai, India., Khan A; Crescent Hospital & Heart Centre, Nagpur, India., Patel K; Health 1 Super Specialty Hospital, Surat, India., Prajapati JS; UN Mehta Institute of Cardiology & Research Centre, Ahmedabad, India., Shah HJ; Kahan Cardiac Clinic, Ahmedabad, India., Reddy RK; Rohini Hospital, Secunderabad, India., Kumar S; Uma Heart Care, Hyderabad, India., Dutta SK; SSKM IPGMER, Kolkata Heart Foundation, Kolkata, India., Chakraborty S; SG Cardiac Care, Bhawanipur, Kolkata, India., Ahmed A; Apollo Gleneagles Cardiologist, Kolkata, Mumbai, India.; Kolkata Heart Foundation, Kolkata, Mumbai, India., Prasad RV; IGIMS, Bihar, India., Chaudhary G; King George Medical University, Lucknow, India., Kumar A; The Heart Center, Kanpur, India., Manjappa M; JSS Hospital, Mysore, India., Shetty S; Justice K.S. Hegde Charitable Hospital, Mangalore, India., Raja P; Praveen Heart Care, Udumalpet, India., Shanmugam VB; Sundaram Hospital, Trichy, India.
Jazyk: angličtina
Zdroj: Cardiology and therapy [Cardiol Ther] 2024 Dec; Vol. 13 (4), pp. 663-677. Date of Electronic Publication: 2024 Nov 06.
DOI: 10.1007/s40119-024-00390-5
Abstrakt: Hypertension, a key modifiable risk factor for cardiovascular diseases (CVD), significantly contributes to premature death and morbidity worldwide. Despite stabilization in age-adjusted global prevalence, the absolute number of hypertensive individuals doubled from 2000 to 2010, largely due to increases in low- and middle-income countries. In 2021, only 21% of hypertensive individuals globally had effective blood pressure (BP) control. In India, hypertension is the leading risk factor for death and disability, with prevalence rates of 24% in men and 21% in women, as reported by the 2019-2020 National Family Health Survey (NFHS-5). Alarmingly, just 25% of rural and 38% of urban hypertensive Indians are undergoing treatment, with only 10% and 20% achieving BP control, respectively. This highlights the hypertension paradox, where clinical inertia and hesitancy in intensifying BP-lowering therapy persist despite the availability of antihypertensive drugs. This expert opinion paper aims to provide a comprehensive evaluation of sacubitril/valsartan in hypertension management, leveraging insights from its approved use in heart failure and examining its benefits and challenges across diverse hypertensive populations. The formulation of this expert opinion involved employing evidence-based methodologies and utilizing all available data. The document underwent scrutiny by expert cardiologists, whose clinical experiences and examination of the evidence and guidelines informed the formation of the expert opinion. This expert opinion paper provides a thorough and informed evaluation of sacubitril/valsartan, highlighting its potential to address unmet needs in BP control, particularly in challenging cases such as resistant hypertension and chronic kidney disease.
Competing Interests: Declarations. Conflict of Interest: Uday M. Jadhav, Saumitra Ray, T. Govindan Unni, J. P. S. Sawhney, Ashwani Mehta, Shantanu Guha, Rajiv D. Karnik, Bhupen N. Desai, Aziz Khan, Keyur Patel, Jayesh S. Prajapati, Hitesh J. Shah, Rama Krishna Reddy, Sanjeev Kumar, Soumya Kanti Dutta, Saujatya Chakraborty, Ashfaque Ahmed, Ravi Vishnu Prasad, Gaurav Chaudhary, Amit Kumar, Manjappa M., Sujal Shetty, Praveen Raja, and Vimalraj Bonagna Shanmugam, have nothing to disclose. Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. All the experts consulted for this paper are listed as authors, and they have consented to their comments being published in a scientific journal.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje